Schering considers alternatives for radiopharmaceutical business

By Jennifer Chiou

New York, Dec. 5 - Schering AG said it is reviewing strategic alternatives for its CIS bio International radiopharmaceutical business as part of its Focus initiative to enhance profitability.

The review includes discussions with parties interested in acquiring its CIS bio International radiopharmaceutical business, which has 750 employees and generated total sales of about €120 million in 2004.

"We are in the process of re-aligning our strategy in the area of diagnostic imaging," executive board member Karin Dorrepaal said in a news release.

"We intend to focus on innovative diagnostic fields of magnetic resonance imaging, computer tomography, optical and molecular imaging."

Schering, a research-based pharmaceutical company, has headquarters in Berlin. It is focused on gynecology and andrology, oncology, diagnostic imaging and specialized therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.